Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc.

101.90
CHF
+49.04
(+92.78%)
3.36EPS
Feb 23Next Earn

Important Dates

Halozyme Therapeutics, Inc.'s next confirmed earnings release is scheduled for February 23, 2027.

Earnings Date2/23/2027

Share Statistics

As of September 30, 2026, Halozyme Therapeutics, Inc. has 113.42M shares outstanding.

Shares Outstanding113.42M

Financial Position

As of September 30, 2026, Halozyme Therapeutics, Inc. maintains a current ratio of 3.88, meaning it holds 3.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -5,884.07, indicating conservative leverage, while an interest coverage ratio of 36.41 demonstrates strong ability to service its debt obligations.

Current Ratio3.88
Quick Ratio3.36
Debt / Equity-5,884.07
Debt / EBITDA4.05
Interest Coverage36.41

Financial Efficiency

CHF

These figures cover the twelve months ended September 30, 2026. Return on invested capital (ROIC) comes in at 19.18 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 17.05, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 19.26, useful for judging operating efficiency across full business cycles. The company generates approximately 3.55M in revenue per employee across its workforce of 423.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.01 indicates how many times Halozyme Therapeutics, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Assets (ROA)17.05
Return on Invested Capital (ROIC)19.18
Return on Capital Employed (ROCE)19.26
Revenue Per Employee3.55M
Employee Count423.00
Inventory Turnover2.01

Taxes

CHF

Over the twelve months ended September 30, 2026, Halozyme Therapeutics, Inc. recorded 141.49M in income tax expense. That works out to an effective tax rate of 25.89, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 546.47M, leaving 404.98M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax141.49M
Effective Tax Rate25.89

Stock Price Statistics

As of the close on October 22, 2026, Halozyme Therapeutics, Inc.'s stock has gained approximately 126.50% over the past 52 weeks.

52-Week Price Change126.50%

Income Statement

CHF

Over the twelve months ended September 30, 2026, Halozyme Therapeutics, Inc. generated 1.50B in revenue and converted that into 404.98M in net income, yielding earnings per share of 3.36. EBITDA reached 669.79M, while operating income came in at 840.83M.

Revenue1.50B
Gross Profit1.24B
Operating Income840.83M
Pretax Income546.47M
Net Income404.98M
EBITDA669.79M
EBIT562.52M
Earnings Per Share (EPS)3.36

Balance Sheet

CHF

As of September 30, 2026, Halozyme Therapeutics, Inc. holds 896.35M in cash and equivalents against 2.71B in total debt, resulting in a net debt position of 1.85B. Total book value stands at -46.09M, with working capital of 1.14B providing operational flexibility.

Cash & Cash Equivalents896.35M
Total Debt2.71B
Net Debt1.85B
Equity (Book Value)-46.09M
Book Value Per Share-0.41
Working Capital1.14B

Cash Flow

CHF

Halozyme Therapeutics, Inc. produced 749.41M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -10.34M in capital expenditures, free cash flow totaled 739.08M - equivalent to 6.36 per share.

Operating Cash Flow749.41M
Capital Expenditures-10.34M
Free Cash Flow739.08M
FCF Per Share6.36

Margins

Over the twelve months ended September 30, 2026, Halozyme Therapeutics, Inc. posted a gross margin of 82.27, reflecting its pricing power and cost economics. The operating margin of 55.91 and net profit margin of 26.93 provide insight into operational efficiency.

Gross Margin82.27
Operating Margin55.91
Pretax Margin36.34
Profit Margin26.93
EBITDA Margin44.54